FDA Approves Resmetirom and Semaglutide for MASH Treatment

UCLA Health has announced the FDA's approval of two medications, resmetirom and semaglutide, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced fibrosis. This significant development marks a turning point in the management of MASH, a serious liver condition that can lead to severe complications such as cirrhosis and liver failure. The approval of these drugs provides new options for patients suffering from this increasingly common disease.

MASH is a more severe form of metabolic dysfunction-associated steatotic liver disease (MASLD), which has seen a rise in prevalence globally, affecting approximately one in three individuals. Risk factors for MASH include obesity, type 2 diabetes, and high cholesterol, with many patients remaining asymptomatic until the disease progresses. Historically, treatment options for MASH were limited, primarily focusing on lifestyle modifications and weight loss, often leading to referrals for bariatric surgery.

The review published in Digestive Diseases and Sciences outlines an algorithm designed to assist healthcare providers in determining the most suitable treatment for their patients. Resmetirom, approved in 2024, functions by targeting thyroid hormone receptors in the liver, aiding in the reduction of liver fat without causing weight loss. In contrast, semaglutide, approved in 2025, promotes weight loss and helps manage blood sugar levels, making it a dual-action option for patients with MASH.

The implications of these approvals are significant for public health, particularly as MASH continues to emerge as a leading cause of liver-related complications. The multidisciplinary approach adopted by UCLA Health, which includes collaboration with cardiologists and nutritionists, emphasizes the importance of a holistic view of patient care. The introduction of these medications is expected to alter the landscape of MASH management, potentially reducing the need for liver transplants and improving patient outcomes.

Looking ahead, ongoing research and clinical trials will be essential in refining treatment protocols and understanding the long-term effects of resmetirom and semaglutide. Healthcare providers are encouraged to monitor patients closely after initiating treatment, with follow-up assessments recommended within one to two months. This proactive approach aims to ensure that patients receive the most effective care tailored to their individual health profiles, ultimately enhancing the quality of life for those affected by MASH.